论文部分内容阅读
目的探讨组蛋白去乙酰化酶6(histone deacetylase 6,HDAC6)在大肠癌组织中的表达,分析其与大肠癌患者临床病理因素及预后的相关性。方法采用免疫组织化学法检测86例大肠癌组织(大肠癌组)及其癌旁正常黏膜组织中(癌旁正常组)HDAC6的表达情况,分析其表达与大肠癌临床病理特征及预后的关系。结果 HDAC6在大肠癌组阳性率(65.1%)高于癌旁正常组(10.5%)(P<0.01);大肠癌组HDAC6蛋白阳性率在患者性别、年龄、浸润深度、肿瘤部位分化程度上差异无统计学意义(P>0.05);有淋巴结转移者HDAC6蛋白阳性率(75.5%)高于无淋巴结转移者(48.5%)(P<0.05),且随TNM分期增加HDAC6阳性率增高,差异有统计学意义(P<0.05);大肠癌组HDAC6蛋白阳性与阴性者3a生存率(89.3%与86.7%)比较差异无统计学意义(P>0.05),但HDAC6蛋白阳性者5a生存率(12.5%)低于阴性者(30.0%)(P<0.05)。结论 HDAC6异常表达可能与大肠癌发生、发展有关,HDAC6可作为诊断大肠癌及评估预后的指标之一。
Objective To investigate the expression of histone deacetylase 6 (HDAC6) in colorectal cancer and its correlation with the clinicopathological factors and prognosis of colorectal cancer. Methods The expression of HDAC6 was detected by immunohistochemistry in 86 cases of colorectal cancer (colorectal cancer group) and its adjacent normal mucosa (paracancer normal group), and its relationship with clinicopathological features and prognosis of colorectal cancer was analyzed. Results The positive rate of HDAC6 in colorectal cancer group (65.1%) was significantly higher than that in normal colorectal cancer group (10.5%) (P <0.01). The positive rate of HDAC6 protein in colorectal cancer group was significantly different in sex, age, depth of invasion and tumor differentiation (P> 0.05). The positive rate of HDAC6 protein in patients with lymph node metastasis (75.5%) was higher than those without lymph node metastasis (48.5%) (P <0.05), and the positive rate of HDAC6 increased with TNM staging (P <0.05). There was no significant difference in the 3a survival rates between HDAC6 protein positive group and negative group (89.3% vs 86.7%) in colorectal cancer group (P> 0.05) %) Was lower than negative (30.0%) (P <0.05). Conclusion The abnormal expression of HDAC6 may be related to the occurrence and development of colorectal cancer. HDAC6 may be used as a marker in the diagnosis of colorectal cancer and prognosis.